Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Takeda Pharmaceutical Co Ltd, an institutional investment manager based in Tokyo, Japan. The report covers the calendar quarter ended June 30, 2024. The filing was signed by Amit Singh, Senior Vice President and Head of Treasury, on February 13, 2025.
Key Financial Metrics
As a Form 13F filing, this document discloses equity holdings rather than the company's operational financial performance (revenue, profit, or cash flow). The following metrics relate to the reported investment portfolio:
- Total Value of Reported Holdings: $232,311,238
- Total Number of Holdings Entries: 15
- Other Included Managers: 1 (Takeda Vaccines, Inc.)
Note: The filing text does not provide data on Takeda Pharmaceutical Co Ltd's own revenue, profit, margins, debt, or liquidity.
Material Changes
The filing text does not provide comparative data for the prior period (March 31, 2024) or detail specific changes in holdings, acquisitions, or dispositions. Therefore, material changes versus the prior comparable period cannot be determined from this summary.
Guidance, Outlook, and Risks
This document is a regulatory disclosure of holdings and does not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's business operations.
Important Facts for Investors to Verify
- Verify the specific 15 equity positions held by Takeda Pharmaceutical Co Ltd as of June 30, 2024, which are detailed in the full schedule of the filing.
- Confirm the relationship and reporting structure with the included manager, Takeda Vaccines, Inc. (File No. 028-24939).
- Note that the total reported value of $232.3 million represents only the specific equity holdings disclosed in this report, not the total assets or market capitalization of Takeda Pharmaceutical Co Ltd.